CHIMERIX INC
CHIMERIX INC (CMRX): 5 pipeline candidates · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.7 months
D/E 0.20 · 0% dilution
Lead: BLA Filed
5 candidates
N/A
N/A
A transparent, data-derived signal for CHIMERIX INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$31.0M
Quarterly Burn
$19.3M
Runway
9.7 mo
Revenue
$57K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| cmx521 | Preclinical |
| dordaviprone | BLA Filed |
| onc201 | Phase 3 |
| onc206 | Phase 1 |
| onc212 | Preclinical |
Frequently asked questions
How many drug candidates are in CHIMERIX INC's pipeline?
CHIMERIX INC (CMRX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CHIMERIX INC's lead drug candidate?
CHIMERIX INC's most advanced tracked candidate is cmx521 (Preclinical) for SARS-CoV-2.
What is CHIMERIX INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CHIMERIX INC has approximately 9.7 months of cash runway.
Who is the CEO of CHIMERIX INC?
North Carolina April is the chief executive officer of CHIMERIX INC (CMRX).
Get the full picture on CHIMERIX INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.